Wells Fargo has initiated coverage on Celcuity Inc (CELC) with an Overweight rating, marking the firm's first assessment of the company's investment potential. This decision comes as Celcuity operates in the biotechnology sector, focusing on cellular analysis and innovative cancer treatments. The company, headquartered in Minneapolis, Minnesota, is known for its lead therapeutic candidate, gedatolisib, which targets specific cancer pathways in advanced breast and prostate cancers.
As of December 11, 2025, Celcuity's stock is priced at $102.24, with a market capitalization of $4.7 billion. The firm has a trailing twelve-month earnings per share (EPS) of -3.67. Upcoming earnings reports include projections for August 12, 2026, with an estimated EPS of -1.11 and revenue of $765,000, and May 12, 2026, with an estimated EPS of -1.05 and no projected revenue.
Analyst ratings like this one provide insight into market sentiment, but they are based on various assumptions and estimates. Investors should consider a range of factors, including company fundamentals and industry trends, before making decisions. It's also important to note that ratings can change as new information emerges, reflecting the dynamic nature of market analysis.
The recent consensus among analysts shows a Buy rating, with 7 Strong Buy, 7 Buy, and 2 Hold ratings. This update underscores the growing interest in Celcuity's innovative approaches and potential in the biotechnology field.